Search Grants — Free, No Account Required

NIMH - National Institute of Mental Health

Abstract Suicide remains a leading public health crisis, claiming over 49,000 lives in 2022. Among college-aged individuals, suicide is the second leading cause of death, with studies indicating that 6.4% of students develop new-onset suicidal ideation, exceeding rates seen in the general population. To address this, researchers increasingly utilize technological tools for real-time suicide risk assessment. While these tools enhance risk detection, they also introduce ethical challenges, particularly in balancing participant safety with scientific validity. Existing protocols for managing suicide risk in research lack empirical validation, creating inconsistencies that delay studies and hinder progress. The proposed study, Structuring Appropriate and Feasible Evaluations of Risk (SAFER), aims to address this gap by developing evidence-based suicide risk management protocols. SAFER will incorporate perspectives from students with lived experience and suicidologists to create and evaluate risk assessment and intervention protocols. The project has three primary aims: (1) examining stakeholder views on the acceptability of suicide risk management protocols, (2) evaluating the effects of different protocols on participant safety, and (3) assessing their impact on data validity. Aim 1 will develop a stakeholder panel consisting of ~16 students with lived experience and ~16 suicidologists. Semi-structured interviews will be conducted until saturation is reached. Aim 2 will assess the perceived acceptability and effectiveness of various suicide risk management protocols among high-risk college students (n=30) and suicidologists (n=10). Participants will evaluate different risk response strategies, including variations in outreach, safety measures, and resource provision. Aim 3 will test the impact of different levels of research personnel outreach on reports of suicidal ideation and behaviors. A cohort of 50 students at risk for suicide will complete daily assessments. Responses will trigger stratified interventions, ranging from automated resource reminders to direct outreach by research staff. Participants will evaluate the acceptability of these interventions at the study’s conclusion. This project will generate empirical data to refine ethical guidelines for suicide risk management, ensuring they are both protective and conducive to research integrity. By balancing participant safety with scientific feasibility, SAFER will provide scalable, evidence-based risk management strategies applicable to diverse research settings. These findings will contribute to national efforts in bioethics, aligning with the Belmont Report principles while addressing critical gaps in suicide research methodologies.

NINR - National Institute of Nursing Research

PROJECT SUMMARY Heart failure affects million adults in the U.S., is associated with high mortality, and is a leading cause for hospitalizations. The long-term objective of this project is to understand the impact of an existing, trauma- informed, community-based, nurse-led heart failure disease management program that provides care to heart failure patients with adverse social determinants of health and unmet social needs (poverty, unstable housing, substance use, mental illness). The Community Heart Failure Program (CHFP) is operated out of a safety-net hospital in the Pacific Northwest and delivers an innovative model of care, where staff provide clinical care in the location of the patient’s choosing, often a shelter, tent, apartment, or other non-clinic-based location. Point- of-care labs and ultrasound support clinical decision-making. Using trauma-informed care principles, including safety, trustworthiness, collaboration, empowerment, and choice, the CHFP and this research project were designed to engage patients with adverse social determinants of health and unmet social needs. This project advances health equity by removing barriers to high quality clinical care and clinical research participation. The short-term objective of this project is to establish feasibility of research study protocols that were designed to evaluate the impact of this innovative existing program. The proposed study is a prospective, longitudinal design (N=40). The specific aims of this project are to: 1) evaluate feasibility of research protocols, 2) compare healthcare utilization 6 months pre- and post-CHFP enrollment, and 3) compare guideline-directed medical therapy (GDMT), biomarkers, and patient-reported outcomes (PROs) at baseline and 3- and 6-months post-enrollment, and 4) examine associations between CHFP conceptual model key components (trust/relationship building, shared-decision making, care coordination, harm reduction) and outcomes (healthcare utilization, GDMT, biomarkers, and PROs). Descriptive statistics will be used for Aim 1. For Aim 2 and 3, paired t-tests (or Wilcoxon signed-rank test) will be used to compare outcomes pre- and post- enrollment, and effect sizes will be calculated to inform future intervention studies in this patient population. For aim 4, correlations (continuous variables) and chi-squared (categorical variables) will be used to examine the direction and strength of associations between key components of the conceptual model and model outcomes, in addition to multivariate regression to determine the independent effect of key components on outcomes. The goals of this project align with the strategic mission of the National Institute of Nursing Research to prioritize research that advances health equity by removing barriers to research participation, optimizes health for individuals and communities, and addresses pressing health challenges.

NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases

Juvenile idiopathic arthritis (JIA) is a chronic illness involving complex treatment plans with varying benefits and risks. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry collects extensive clinical and patient-/parent-reported data on over 12,000 North American children with JIA. However, the Registry lacks data on healthcare utilization, medication dispensing, and patients who do not consent, limiting its utility. Claims databases are large population-based datasets that permit study of large populations, rare diseases, and wide range of outcomes. However, claims data lack potentially critical clinical measures such as disease activity and patient-/parent-reported outcomes. To address these gaps and facilitate future observational and interventional clinical studies, we will perform the Study to Probe & Appraise Registry-Claims Linkage for Juvenile Idiopathic Arthritis (SPARCLe-JIA). This study aims to assess CARRA Registry data linked with the Komodo national claims database (>50,000 children and youth diagnosed with JIA). This linked dataset will allow for a comprehensive evaluation of the Registry's data coverage, consistency, and utility for conducting rigorous and broadly applicable research on JIA. The specific aims are: 1) to compare the characteristics of linked versus unlinked patients with JIA within the Registry and claims data; 2) to compare rates of uveitis and hospitalizations across datasets and evaluate whether use of linked data results in greater validity for an applied question on tumor necrosis factor inhibitors and hospitalized infection; and 3) to investigate how delays in biologic drug dispensing affect subsequent disease activity—a proof-of-concept study that can only be done using linked Registry and claims data. SPARCLe-JIA employs advanced analytical approaches to address critical gaps in pediatric rheumatology research by testing a novel and powerful resource for JIA research. The validation of this linkage between Registry and claims data will set a new standard in the field, providing a model that can readily be applied to other pediatric rheumatic diseases captured by the CARRA Registry, including systemic lupus erythematosus and juvenile dermatomyositis. The linked dataset will enable a wide variety of future investigations, including studies on risk factors, outcomes, healthcare utilization, comparative effectiveness, drug safety, biomarkers, adherence, deprescribing, mental health, and the transition from pediatric to adult rheumatology care, thereby improving JIA management and informing clinical and policy decisions. Through these aims, SPARCLe-JIA will enhance the utility of the CARRA Registry for future observational and interventional studies that will ultimately improve the management, monitoring, and outcomes of people with JIA and other pediatric rheumatic diseases.

NIMH - National Institute of Mental Health

PROJECT TITLE Suicidal Thoughts and Behaviors Among Youth Victims of Human Trafficking PROJECT SUMMARY / ABSTRACT Youth suicide is a significant public health concern in the United States. One population found to have higher rates of suicidal behavior are youth victims of human trafficking, a crime involving the exploitation of a person under the age of 18 for labor, services, or commercial sex. Minimal consideration has been given to the risk for suicide in youth victims of human trafficking. The few identified studies show up to 75% of youth victims of human trafficking endorsed lifetime suicide ideation and between 40% to 50% reported past suicide attempts. Evidence further suggests youth victims of human trafficking experience high rates of unmet physical and mental health needs, and that most health care providers are ill equipped to recognize and respond to these youth. The development of suicide prevention strategies tailored for youth victims of human trafficking is hampered by the limited evidence regarding risk in these highly vulnerable youth. Even less is known about successful approaches to implement these strategies. Victims of human trafficking represent an important understudied youth population that merits attention in the suicide prevention research. This proposed retrospective cohort study will uniquely identify characteristics (individual, familial, community) and clinical factors (mental health history, physical health conditions, health service utilization) that contribute to the risk for suicide among youth victims of human trafficking presenting to a juvenile court. Several states have implemented “Safe Harbor” laws that aim to avoid arrest and prosecution of trafficking victims, however many of these victims still find themselves involved with the legal system. Utilizing a mixed methods approach, this proposal will reinforce the interpretation of quantitative findings with data from key stakeholder interviews to gain additional insight on suicide risk in this youth population and to better inform targeted interventions. Consideration will be given to potential facilitators and barriers to intervention with youth human trafficking victims, including when, how, and where to intervene. This innovative study is the first to examine the complex array of factors linked to suicide risk in youth trafficking victims and to consider a systematic approach for translating these findings into tailored suicide prevention strategies for this high- risk population. The rationale for this research is that an improved understanding of youth victims of human trafficking at elevated risk for suicide is crucial to advance preventative interventions and reduce youth suicide.

NIH

BACKGROUND: Suicide is a chief concern in Veterans, particularly following a mental health stay. The Department of Veterans Affairs (VA) has invested heavily in strategies to prevent suicide in Veterans who are at risk of suicide following a Veterans Health Administration (VHA) mental health stay. These interventions, however, do not reach another high-risk population, namely Veterans who access VA-purchased care in the community (i.e., Community Care). This is particularly concerning because an increasing number of Veterans are using VA-purchased care. While Veterans are at high risk of suicide following a Community Care mental health stay, there is little knowledge about effective strategies to mitigate suicide risk in this population. A promising suicide prevention strategy, called the VA Brief Intervention and Contact Program (BIC), has been developed. VA BIC is designed to meet the unique needs of Veterans. Pilot studies of VA BIC in VHA settings have suggested that VA BIC may address key factors related to suicide risk during care transitions including social connectedness and treatment engagement. Based on these promising results and given the critical gaps in suicide prevention care in Veterans who are psychiatrically hospitalized in Community Care settings, it is essential to determine whether VA BIC can reduce suicide risk in this high-risk population. OBJECTIVES: The long-term goal is to design, study, and improve interventions to prevent death by suicide in Veterans. The overall objective of this proposed clinical trial is to determine whether the VA BIC intervention is an effective strategy to reduce suicide risk in Veterans who are admitted to Community Care mental health units. The short-term goal is to test whether the VA BIC intervention can decrease suicidal ideation after a Community Care mental health stay and increase [engagement in mental health care and social connectedness.] The central hypothesis is that VA BIC will [decrease suicidal ideation after discharge] as compared to treatment as usual (TAU). It is hypothesized that VA BIC will [increase engagement in mental health care and social connectedness after discharge] as compared to TAU. The expected outcome of the trial is to ascertain the efficacy of VA BIC in decreasing suicidal ideation and [increasing engagement in mental health care and social connectedness] following a Community Care mental health stay. The trial will inform the design of a future Cooperative Studies Program (CSP) multi-site trial that is powered to test the effect of VA BIC on suicide attempts in Veterans with a psychiatric hospitalization in a Community Care facility. METHODS: A randomized controlled trial of VA BIC will be carried out in Veterans who are psychiatrically hospitalized at Community Care hospitals located in [Northern] New England. Eligible Veterans will be recruited over a three-year timeframe and will be randomized to VA BIC plus TAU, or TAU alone. Participants will be followed for a total of [nine] months. Outcomes will be gathered at baseline and at [3, 6, and 9] months [post baseline.] [A generalized linear mixed model (GLMM)] will be used to determine whether VA BIC results in a significant decrease] in suicidal ideation. A GLMM will [also] be used to learn whether VA BIC results in a significant [increase] in [engagement in mental health care and social connectedness]. An exploratory analysis will examine the effect of VA BIC on suicide attempts. IMPACT: Little is known about effective strategies to prevent suicide in Veterans who are treated in Community Care settings. This proposal will address this concerning knowledge gap by testing a highly promising suicide prevention strategy in Veterans who are psychiatrically hospitalized in Community Care hospitals. The results of the trial will not only determine the impact of VA BIC on suicide risk in this population but also lead to a future CSP trial that is powered to detect the effect of VA BIC on suicide attempts. In the end, the proposal trial will enable the VA to identify a highly effective intervention to prevent suicide in a vulnerable Veteran population that may have little or no interaction with VA providers during a chief period of risk.

NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development

ABSTRACT Unhealthy and problematic use of technology and digital media (TDM) in childhood and adolescence have increased in prevalence over the past 20 years, with negative consequences for sleep, physical activity, in- person socializing, emotional health, and family relationships. However, interventional research is a major gap in the literature; no evidence-based approaches exist to support healthy TDM use in children. This proposal is conceptually grounded in the Interactional Theory of Child Problematic Media use, which posits that drivers of unhealthy TDM use include: 1) psychosocial factors such as family stress, 2) parent-child factors such as mood dysregulation, parenting self-efficacy, and maladaptive coping, and 3) technology factors such as engagement-prolonging design. Therefore the proposed randomized controlled trial will test two interventional components: Problem-Solving Education (PSE), an evidence-based cognitive-behavioral strategy that teaches parents problem solving skills as a means of managing parental stress, increasing self-efficacy and adaptive coping, and following through on goals; and TDM Settings assistance to enable parental controls on screen time, content, contacts, and reducing engagement-prolonging designs. These approaches leverage the expertise of the MPIs: Dr. Radesky is co-Medical Director of the American Academy of Pediatrics (AAP) Center of Excellence on Social Media and Youth Mental Health, through which she has created resources and guidance for healthy TDM use in families, while Dr. Kistin is an expert in community-based interventions to support problem-solving, self-efficacy, and positive parenting in stressed families. The application proposes to conduct a type 1 hybrid 2 x 2 randomized controlled trial design in 300 school-aged children (ages 6-10 years) and their parents, a developmental window when many children receive their first gaming console and/or mobile device, but parents still have some degree of control over TDM use. Parent-child dyads (N=300) will be randomized to the following study arms: 1) PSE only; 2) TDM Settings only; 3) PSE+TDM Settings; or 4) Control (AAP resources). Families will be followed for 4 months to assess the following Specific Aims: SA1) Primary outcomes: Test the effects of PSE alone, TDM Settings alone, and combined PSE+TDM Settings versus control on child mood dysregulation (externalizing/internalizing behaviors) and problematic media use symptoms. SA2) Secondary outcomes: Test the effects of PSE alone, TDM Settings alone, and combined PSE+TDM Settings versus control on child daily TDM duration, use of age-inappropriate content, bedtime media use, parent-child communication about media, and parent stress. SA2a) Exploratory outcomes: Measure intervention effects on the frequency of children’s in-person socializing, outdoor play, alternative activities, and positive family routines. SA3) Dissemination and implementation: Using the RE-AIM framework, evaluate intervention reach, adoption, fidelity, and other factors that impact future dissemination and sustainability in pediatric settings.

NIDCD - National Institute on Deafness and Other Communication Disorders

PROJECT SUMMARY The purpose of this Mentored Patient-Oriented Research Career Development Award application is to prepare Brittany Manning, PhD, CCC-SLP, for a career as an independent clinician-scientist with expertise in implementation science. The proposal includes specialized activities, mentorship, and research to support training in (1) community-engaged, co-design methods, (2) clinical trials of early language intervention, and (3) embedded implementation science frameworks. With specialized training in implementation science, Dr. Manning will build on her expertise in the intersection of early language delays and mental health vulnerabilities to adapt and implement interventions to support the complex needs of real-life children with language delays/disorders. Children with language delays are twice as likely to display elevated levels of irritability as their non-language-delayed peers. Elevated child irritability (i.e. a low threshold for frustration and disruptive behaviors) makes it difficult for speech-language pathologists (SLPs) to engage children in language facilitating interactions in intervention sessions. Evidence-based emotion/behavior management techniques are effective in reducing child irritability. However, despite adaptations for other settings (home, school) and implementers (parents, teachers), evidence-based emotion/behavior management techniques and training materials have not been adapted with early language intervention in mind. Thus, the objective of this research proposal is to create SKILL: Supporting Kids with Irritability in Language Learning, an intervention package of adapted emotion/behavior management techniques for early language intervention and a brief, online training for SLPs. Equipping SLPs with evidence-based irritability management techniques is critical for supporting language learning during early language intervention sessions. The research project will pursue the following aims: (1) Using a community-engaged, co-design process, adapt evidence-based emotion/behavior management for early language intervention with iterative input from SLPs, mental health clinicians, and parents; (2) conduct a pilot hybrid effectiveness-implementation type 1 trial to examine the feasibility/acceptability/preliminary effectiveness of SKILL in improving early language intervention outcomes; (3) elucidate barriers/facilitators and implementation strategies to support SKILL’s uptake. Results from the pilot study will inform the optimization of SKILL and the design of subsequent, fully powered hybrid effectiveness-implementation type 1 trial submitted under an R01 mechanism. This work has the potential to improve care for a substantial portion of children with language delays/disorders, improve SLP confidence and satisfaction in working with children with complex needs, and advance implementation science in the field of Communication Disorders.

NIMH - National Institute of Mental Health

PROJECT SUMMARY/ABSTRACT We propose to broadly disseminate and extend intuitive, powerful cloud-based resources for optical brain mapping that facilitate efficient, accurate, and standardized processing that will harmonize the emerging set of optical measurement strategies within the growing ecosystem of network level analyses used throughout the greater brain mapping community. The neuroimaging community faces numerous challenges in data collection, preprocessing, estimation of brain connectivity, and analyses of relationships between brain connectivity and behavior. An ever-expanding community of researchers are employing optical methods based on functional near infrared spectroscopy (fNIRS) in order to infer pathophysiological states of the brain for detection/ characterization of disease or cerebral hemodynamics for understanding human brain health, development, and aging. Recent developments of high-density diffuse optical tomography (HD-DOT), a silent, flexible, and scalable technology have demonstrated dramatically improved anatomical specificity and image quality over traditional fNIRS. Further, recent developments in wearable HD-DOT, even using frequency domain and time resolved strategies, open the door to unconstrained mapping of naturalistic human brain function with superior image quality than previously possible. Given the growing worldwide adoption of fNIRS and HD-DOT methods and further developments of next-generation optical brain mapping methods via the BRAIN Initiative, there is an urgent and present need for standardized, accessible and flexible tools that directly support workflows from optical tissue parameter recovery to functional brain mapping to relating variance in brain function to behavior and outcome. Our team is funded by U24NS136402 to address these needs in the optical brain mapping community by developing and validating computational tools including NIRFASTer, NeuroDOT, and Network Level Analyses (NLA), for tissue parameter recovery, optical brain mapping, and model-based connectome-wide association studies of brain function and behavior, respectively. We address the unmet needs for data resources with: (1) greater dissemination and training for our tools with detailed documentation, training materials, and international workshops, (2) cloud deployment of our software to increase scale and accessibility, while easing the computational burden for the user, and (3) expanded utility of these sustainable, flexible tools to meet the evolving needs of users at the forefront of optical imaging technology development. This R50 will support a Research Software Engineer (RSE) to be an established senior RSE through gaining deeper experience expanding development, maintenance, and dissemination of the U24-supported tools while enhancing her skills and knowledge of best software engineering practices, FAIR standards, and optical neuroimaging methods, as well as common and emerging neuroimaging algorithms. This proposal directly supports execution of BRAIN Initiative goal 7 that seeks to integrate new technological and conceptual approaches to discover how dynamic patterns of neural activity are transformed into cognition, emotion, perception, and action in health and disease.

NIMH - National Institute of Mental Health

Project Summary/Abstract Parvalbumin-expressing inhibitory interneurons (PVs) are linchpins of synchronized neural computation. They are specialized to provide rapid perisomatic inhibition onto excitatory neurons (ENs) and are the primary source of inhibitory control in hippocampal CA1 – a region critical to learning and memory. PV dysfunction, circuit hyperactivity, and cognitive impairment are hallmark features of schizophrenia and are also observed in animal models with targeted deletion of glutamate receptors in PVs, implicating disrupted glutamatergic input onto PVs as a potential contributor to the disorder. While the underlying mechanisms remain unclear, the onset of schizophrenia in late adolescence suggests circuit instability may result from a gradual deterioration of PV synapse stability. Decades of research support a continuum of mechanisms at different spatial scales, from individual synapses to the network-level, through which activity homeostasis is achieved in ENs. While numerous studies have shown that PVs are plastic in learning-related contexts, how their synaptic inputs remodel following chronic alterations in network activity is not well understood. Similarly, homeostatic plasticity, of individual synapses on INs has not been explored in vivo and the mechanisms that allow PVs to preserve stability under circuit challenge remain poorly understood. This proposal will utilize a combination of high-resolution confocal imaging, circuit mapping techniques and electrophysiology to test the hypothesis that PV homeostatic remodeling helps maintain stable circuit behavior in the face of network challenge. In Aim 1, I will examine how glutamatergic synapses onto PVs structurally and functionally respond to chronic changes in circuit activity. Aim 2 then investigates the PV-enriched NMDA receptor subunit GluN2D, a schizophrenia risk gene, as a potential mechanism enabling PVs to sense changes in local activity and initiate compensatory responses. Together successful completion of the proposed experiments may help identify entry points for addressing an unmet need in restoring excitation onto PVs in conditions characterized by PV hypofunction such as schizophrenia, epilepsy, and autism. Through this proposal, I will be thoroughly trained in molecular biology, circuit-mapping, electrophysiology and genetic perturbation strategies. In addition, mentorship from Dr. Bygrave and co-sponsor Dr. Dulla will provide an environment with exceptional guidance and rigorous training, access to all necessary equipment, and opportunities for networking, mentorship, and career development activities. Collectively, this proposal will provide me with the scientific training and growth necessary for establishing the foundations for a future successful career as an independent academic scientist.

NIMH - National Institute of Mental Health

Abstract 22q11.2 deletion syndrome (22q11.2DS) is the most common chromosomal microdeletion in humans, with an incidence of ~1/4000 live births. Symptoms associated with 22q11.2DS are broad and unpredictable, ranging from cardiac defects to cognitive deficits and increased risk of schizophrenia. 22q11.2DS patients commonly experience learning delays and deficits in working memory, which have lifelong quality of life impacts. Notably, using a recently developed full deletion mouse model of 22q11.2DS, our lab has discovered dramatic deficits in synaptic structural plasticity in the hippocampal CA1 region. Our central hypothesis is that the learning and memory deficits of 22q11.2DS 22q patients are due to profound alterations to glutamatergic synaptic plasticity and signaling in the hippocampus. To test this hypothesis, we will investigate the synaptic signaling mechanisms (Aim 1) and single-cell gene expression profiles (Aim 2) underlying disruptions in plasticity of hippocampal CA1 neurons in 22q11.2DS model mice. Genome-wide sequencing suggests 22q11.2DS presents a threshold lowering effect for schizophrenia, and that the 22q deletion creates a vulnerable substrate for the manifestation of other schizophrenia risk factors. Perturbations in pathways that support synaptic structural plasticity likely contribute to this increased vulnerability to schizophrenia in 22q11.2DS patients. The proposed experiments will fill a gap in knowledge concerning the molecular and cellular mechanisms responsible for deficits in place memory and working memory associated with 22q11.2DS. Knowledge of these signaling pathways move us closer to developing therapeutics to manage the cognitive effects of this unpredictable and impactful disease.

NIMH - National Institute of Mental Health

ABSTRACT Synapses form trillions of connections between billions of neurons in the brain to establish neural circuits that allow us to sense, think, act, learn, and remember. Our goal is to understand how synapse structure supports learning and memory with a focus on dendritic spines, the tiny protrusions that host most of the excitatory synapses in the brain. While most neuroscientists agree that synaptic structural changes are vital for learning and memory, the cellular and molecular mechanisms that protect recent synaptic changes from being overwritten by ongoing plasticity remain ill-defined. Our three-dimensional reconstructions from serial section electron microscopy (3DEM) reveal distinct subregions of the postsynaptic density (PSD) where active zones (AZs) are associated with presynaptic vesicles and nascent zones (NZs) have no presynaptic vesicles. At the onset of long-term potentiation (LTP), presynaptic vesicles are rapidly recruited to the NZs, converting them to AZs. Protein filaments shorten and draw docked presynaptic vesicles closer to the enlarged AZs, and recruit vesicles to dock at weak AZs. This evidence of presynaptic plasticity would increase the area of release and probability of postsynaptic receptor response. The recovery interval following saturation of LTP is 1-4 hours depending on the preparation. During this interval, new NZs form, primarily on spines containing smooth endoplasmic reticulum, a local resource for regulating calcium and trafficking of lipids, proteins, and organelles. Clusters of spines form in the vicinity of these enlarged spines. We hypothesize that synapse-specific expansion of NZs during LTP provides a basis for learning and the advantage of spaced over massed learning to establish long- lasting memories. Furthermore, we hypothesize that LTD is driven by the conversion of AZs to NZs and ultimately elimination of spines without AZs. To address these hypotheses, we propose multidisciplinary approaches to investigate the cellular and molecular mechanisms that drive the conversion of NZ to AZ and limit plasticity at synapses—including slice physiology, optogenetics, molecular genetics and pharmacology, glutamate uncaging, and tomographic 3DEM of synapses along activated axons labeled with APEX. Our Specific Aims are: Aim 1) Determine the specificity of NZ to AZ conversion during synapse enlargement, resource utilization, and spine clustering underlying the saturation, recovery, and enhancement of LTP. Aim 2) Test whether saturating LTP at an isolated dendritic spine is sufficient to fill NZs and determine the role of PSD-MAGUK proteins and their interacting partners in recovery of LTP from saturation. Aim 3) Determine how the saturation and recovery of long-term depression (LTD) alters the structure of AZs, NZs, and spines, and influences the subsequent capacity for LTP. Outcomes promise new insights about synaptic mechanisms of learning and memory and new targets for understanding and treating learning disabilities.

NIMH - National Institute of Mental Health

PROJECT SUMMARY: This R21 proposal seeks to uncover how sleep and circadian rhythms (CR) regulate protein synthesis at neuronal synapses, key cellular sites for learning and memory, by defining the “synaptic translatome”: newly synthesized proteins localized at synapses. Sleep is essential for brain health and survival. Sleep need accumulates during wake and is resolved only by sleep. Although sleep behavior is governed by specific brain circuits, sleep need is distributed throughout the nervous system. Synapses are central to this distributed sleep need, as they undergo plastic changes during wake and are subsequently remodeled during sleep to support synaptic homeostasis, memory consolidation, and brain development. Synapses have thus emerged as a conserved and distributed 1. locus of sleep need, 2. target of restorative sleep function, and 3. site of dysfunction with sleep loss. Neurons rely on localized protein translation at synapses, far from the cell body, to support these plastic changes. The timing of this process is influenced by the circadian clock, a cellular mechanism involving “clock genes” that operate in nearly all cells. Previous multi-omic studies of purified forebrain synapses revealed that both CR and sleep need regulate the trafficking of mRNAs to synapses and the timing of their translation. Defining the synaptic translatome in response to wake/sleep states and circadian time is essential to revealing the biochemical basis of sleep’s restorative functions and its interactions with the CR. This research also addresses the intersection between sleep, synaptic development, and neurodevelopmental disorders (NDDs) such as Autism Spectrum Disorder (ASD) and Schizophrenia (SCZ). Disruption of sleep and circadian rhythms is a common feature in NDDs, and many NDD-associated genes encode synaptic proteins, such as SHANK3. Prior work using SHANK3+/- mice, a model for genetic vulnerbaility for ASD and SCZ, demonstrated that early life sleep disruption (ELSD, postnatal days 14–21) leads to persistent, sex-specific behavioral changes, highlighting an interaction between sleep, genetic vulnerability, and sex. Synapse-specific proteomic analysis in these mice showed that ELSD disrupts synapse maturation, particularly affecting protein synthesis and mRNA biology. To build on these findings, the proposal uses biorthogonal non- canonical amino acid tagging (BONCAT) to label newly synthesized proteins, combined our established synapse fractionation and quantitative proteomics to define the synaptic translatome. Aim 1 will characterize how the synaptic translatome is shaped by CR and sleep deprivation across development in juvenile, adolescent, and adult mice, across brain regions including cortex, hippocampus, and striatum. Aim 2 will determine how ELSD alters the synaptic translatome in wild-type and SHANK3+/- mice, to better understand how sleep disruption impacts synapse maturation in genetically vulnerable brains. This R21 will establish BONCAT as a powerful discovery platform to study synaptic protein synthesis in vivo, enabling novel insights into the mechanisms of sleep function, and how its disruption contributes to the etiology of neurodevelopmental disorders.

NIMHD - National Institute on Minority Health and Health Disparities

Revised Abstract Section ABSTRACT Sickle cell disease (SCD) is a chronic condition characterized by painful vaso-occlusive crises, fatigue, and frequent hospitalizations, which significantly impact mental health and quality of life. Depression affects 25– 35% of SCD patients, yet current screening tools, such as the Patient Health Questionnaire-9 (PHQ-9), fail to account for the overlap between somatic symptoms of depression and SCD-related physical symptoms. This leads to misclassification, resulting in inaccurate diagnoses and suboptimal treatment. This study aims to develop and validate a novel depression screening instrument tailored for SCD patients by empaneling a patient workgroup to conceptualize the depression experience among people with SCD and identify key symptom difference between depression and SCD-related distress (AIM 1); Modify the PHQ-9 screening tool by incorporating patient and clinician input to ensure accurate differentiation between depressive symptoms and SCD manifestations (AIM 2); and establish construct validity through psychometric analysis, including classical test theory and item response theory, to confirm internal consistency, test-retest reliability, and divergence from anxiety and PTSD measures (AIM 3). By addressing a critical gap in mental health screening for SCD patients, this study will improve diagnostic accuracy, enhance clinical decision-making, and reduce health disparities. The validated tool will facilitate appropriate mental health interventions, ultimately improving patient outcomes and quality of life.

NIMH - National Institute of Mental Health

PROJECT SUMMARY/ABSTRACT Globally, there were 1.3 million new HIV infections in 2023, despite expanded access to biomedical HIV prevention products with high efficacy. Implementation strategies are needed to expand the reach of HIV risk screening and to facilitate the use of biomedical prevention among persons with risk. These implementation strategies are often delivered at the group-level or induce changes at the group-level (e.g., health clinics or health systems). Cluster randomized trials (CRTs) are integral to evaluating and optimizing strategies deployed at the group-level. CRTs provide an exciting opportunity to evaluate strategies aiming to both improve reach into the target population and health outcomes among persons reached. However, these CRTs create a complex missing data problem: the strategy improves outcomes directly and indirectly; yet, outcomes are only measured among persons reached. While machine learning can facilitate adjustment for missing data in simpler CRT settings, new methods are needed to minimize bias arising from this common CRT setting. CRTs also provide an exciting opportunity for intervention optimization by evaluating for whom and in what context the strategy works best. However, existing methods to evaluate effect heterogeneity in CRTs are prone to false conclusions (i.e., Type-I and Type-II errors). While machine learning can facilitate data-driven evaluation of effect modification in individually randomized trials, CRTs present distinct challenges due to their small effective sample sizes. In this proposal, we will address these crucial gaps in the analysis of CRTs. To do so, we will develop, apply, and disseminate new Targeted Machine Learning Estimators (TMLEs) to minimize bias due to missing data and to facilitate data-driven evaluation of effect modification. TMLE combines formal causal modeling, statistical theory, and machine learning to improve the accuracy, precision, and relevance of our findings. This proposal has the following aims. We will develop new TMLEs to minimize bias due to missing data and robustly evaluate overall effectiveness in CRTs of strategies that aim to improve both reach and health outcomes (Aim 1A). We will combine these TMLEs with novel sample-splitting and multiple testing procedures to data-adaptively identify and evaluate effect heterogeneity at multiple levels (Aim 1B). In secondary data analyses of two CRTs, we apply the proposed methods to generate new insights about the effectiveness and implementation of an HIV prevention strategy when offered at scale and when adapted to a new context (Aim 2). We will disseminate the proposed methods through a user-friendly and interactive website – facilitating the rigorous and reproducible use of our new methods (Aim 3). This work is timely and significant given the role of CRTs in evaluating and optimizing strategies to prevent HIV and other chronic conditions, such as hypertension, diabetes, and cardiovascular disease.

NIMH - National Institute of Mental Health

Project Abstract In recent years, the prevalence of depression has risen, and with it, the prescribing of serotonergic antidepressants. Approximately 13.2% of adults aged 18 and over report using antidepressant in the past 30 days. Anhedonia (loss of interest or pleasure in previously rewarding activities) is a common symptom of depression. First-line antidepressants, selective serotonin reuptake inhibitors (SSRIs), can effectively lift low mood, but often come at the cost of further blunting emotion and reward-processing. In contrast, psilocybin (a 5HT-2A psychedelic) has shown promise in alleviating anhedonia and improving emotional range, even outperforming SSRIs in head-to-head trials. Emerging clinical research supports the safety and efficacy psilocybin in individuals currently taking an SSRI, offering a promising new adjunctive treatment option for those experiencing residual anhedonia. Despite this potential, the neural mechanisms underlying psilocybin's therapeutic effects on anhedonia remain poorly understood. Parallel fronto-limbic circuits—connections between the medial prefrontal cortex (mPFC) and limbic system—regulate motivation and emotional response. One crucial circuit, connecting the pregenual anterior cingulate cortex (pgACC) and the nucleus accumbens (NAcc), forms the core of the brain’s reward system and is implicated in anhedonia. In anhedonia, activity and connectivity in this pgACC-NAcc circuit is suppressed. SSRIs may further suppress this circuit, leading to residual deficits in motivation and pleasure. This study will use a clinical trial to assess the effects of a single dose of psilocybin (25 mg single dose) or control (psilocybin 1mg) in individuals experiencing SSRI-induced anhedonia. We will utilize Precision Functional Mapping (PFM), a novel fMRI technique enabling individual-specific brain mapping, to investigate how psilocybin modulates fronto-limbic circuitry in individuals with SSRI-induced anhedonia. In addition to PFM, we will use well-validated task-fMRI (emotional processing, monetary incentive delay) to probe key fronto-limbic circuits. Then we will test the ability of psilocybin to engage reward circuitry relevant to anhedonia. This work will advance our mechanistic understanding of anhedonia, identify biomarkers for targeted treatment, and potentially lead to more effective therapies.

NIMH - National Institute of Mental Health

Timely follow-up outpatient mental healthcare after psychiatric hospitalization is associated with improved outcomes, including better medication adherence, increased outpatient treatment utilization, reduced emergency department visits and psychiatric readmissions, and lower risk of suicide related outcomes. However, many adolescents do not receive recommended follow-up care post discharge. Social needs, defined as social and financial challenges such as financial strain and housing, food, and transportation insecurity, may be key barriers to timely follow-up care. Addressing social needs during and immediately following hospitalization may improve service engagement and mental health outcomes. This K01 project responds to a national push, endorsed by the American Academy of Pediatrics, to integrate screening and intervention for social needs into clinical settings. The proposed study aims to develop a clinical pathway that universally identifies and addresses social needs for adolescents who are psychiatrically hospitalized. The project will focus on youths 12 to 17 years with psychiatric hospitalizations at Nationwide Children’s Hospital in Columbus, Ohio and on social needs modifiable through available resources in the Columbus area. The specific aims include: 1) Assess perspectives of adolescent patients, their caregivers, health system staff and leadership, and community organizations on the health system’s role in identifying and assisting youths with social needs; 2) Examine causal associations between social needs and post-discharge mental health services utilized by adolescents following psychiatric hospitalization; and 3) Apply intervention mapping to develop a clinical pathway to identify and support adolescents with unmet social needs during and immediately after psychiatric hospitalization. This proposal will provide Dr. Llamocca with advanced training and vital skills to leverage findings from secondary data analysis to develop clinical pathways, in collaboration with clinical scientists, to address social needs and improve youth mental health outcomes. Dr. Llamocca will be mentored by an experienced team, including co-primary mentors Drs. Jennifer Hughes and Cynthia Fontanella, co-mentors Drs. Jordan Braciszewski, Susan Shortreed, and Alicia Bunger, collaborator Dr. Laura Chavez, and consultants Drs. Arvin Garg and Yunyu Xiao. The team has expertise in youth suicide prevention, pediatric social needs interventions, causal inference methodology, implementation science, and intervention development. Training will focus on: 1) acquiring qualitative and mixed methods research skills, 2) developing expertise in analyzing electronic medical record data utilizing causal inference methodology, and 3) gaining knowledge in adapting and evaluating interventions. This K award will launch Dr. Llamocca’s career as an independent mental health services researcher dedicated to developing data-driven strategies to address social needs and reduce suicide risk.

NIMH - National Institute of Mental Health

Abstract. Angelman syndrome is a severe neurodevelopmental disorder caused by the loss of maternal UBE3A, a neuronally imprinted gene that encodes the UBE3A ubiquitin ligase. The loss of UBE3A activity causes the dysregulation of an ensemble of proteins in neurons, but the identity of Angelman syndrome-relevant substrates and the pathways they affect remain poorly understood. The primary goal of the proposed research is to understand the neuronal pathways affected by the loss of UBE3A activity and to leverage this information for therapeutic design. Preliminary proteomics studies identified asparagine synthetase (ASNS) as a substrate of UBE3A. ASNS is best studied for its induced expression during the integrated stress response (ISR), an emerging pathway that is dysregulated in various neurodevelopmental disorders. Activation of the ISR suppresses protein synthesis in response to diverse stressors via phosphorylation of the α-subunit of eukaryotic translation initiation factor 2 (p-eIF2α). In human neurons and in brains of Angelman syndrome model mice that lack a copy of maternal Ube3a (Ube3am+/p+), ASNS protein levels are elevated. Moreover, Ube3am+/p+ animals exhibit altered global amino acid levels and increased p-eIF2α levels. Genetic correction of ASNS overabundance improved many behavioral phenotypes and microcephaly, the primary neuroanatomical deficit in Angelman syndrome. Based on these preliminary findings, this proposal aims to: 1) characterize the postnatal targeting of ASNS and ISR in a mouse model of Angelman syndrome, and 2) to characterize the role of ASNS in neuronal development. If successful, this work will provide important therapeutic targets for the treatment of Angelman syndrome and offer new insights for the role of ASNS and the ISR in neuronal development and disease.

TELUS

TELUS invests in youth health and well-being, supporting mental health, digital literacy, and community programs through grants across Canada.

NIH

Background: Psychological distress in Veterans Affairs (VA) primary care patients is common and often not adequately treated. The VA has a suite of evidence-informed mobile health applications (mHealth apps) for psychological distress that are frequently downloaded, but most Veterans do not use them enough to experience health benefits. Support from helping professionals, such as peer specialists, can increase app use and health benefits. Our team found that peer-supported mHealth is feasible to deliver in VA primary care, increases app engagement and is associated with high satisfaction and improved Veteran health. However, not all individuals need the same amount of support when using mHealth. This study will test an adaptive intervention using a SMART design to match patient need with specific doses of peer support for mHealth. Significance: Our long-term goal is to improve the health of Veterans with psychological distress by developing a brief and efficient stepped-care intervention that can be feasibly implemented in VA primary care settings. This proposal is highly aligned with the priorities of our operational partners in the Offices of Mental Health and Patient Centered Care & Cultural Transformation and VA BBMH. The findings will support the VA- wide expansion of the Peers in PACT program, per recent STRONG Act legislation. Innovation & Impact: Key innovations include the use of a SMART design to develop an adaptive intervention for a high-priority patient population and the novel application of the Supportive Accountability model in which human support is critical to enhancing adherence to mHealth interventions. The proposal will also provide much needed data on the effectiveness of peers to deliver brief, structured interventions. Specific Aims: 1) Test the effectiveness of a) stage 1 (Peer mHealth vs. Self-Managed mHealth), b) stage 2 interventions (4 sessions of Peer mHealth vs. Peer Whole Health) among slow responders and c) the embedded stepped-care treatment sequences on psychological distress and secondary outcomes (e.g., app use, cost, mental health service use, symptoms, functioning) at 12 weeks. 2) Examine candidate tailoring variables as predictors of outcomes in a) stage 1 (i.e., motivation, coping self-efficacy) and b) stage 2 (i.e., app use and unmet social needs). Race/ethnicity and sex/gender will also be explored as moderators. 3) Assess barriers and facilitators to implementing adaptive interventions for peer mHealth in PACT by interviewing key VHA leadership, staff and Veteran stakeholders. Methodology: Participants (N=384) with significant psychological distress who are not engaged in specialty mental health care will be randomized at Stage 1 to receive either Self-Managed mHealth or one peer phone call to support mHealth. Participant response, defined as a reliable decrease in psychological distress (5-point decrease in any DASS-21 subscale) will be measured after 4 weeks. Stage 2 randomization will assign slow responders to step-up to additional mHealth peer phone calls or an alternative peer support model (peer- delivered Whole Health). Stage 1 early responders will continue/ step-down to Self-Managed mHealth. All participants will be reassessed at 12, 16 and 24 weeks post-enrollment. Psychological distress is the primary outcome. Secondary outcomes include app use, mental health service use, cost, psychological symptoms (e.g., depression, anxiety, stress, PTSD, anger, sleep), and functioning (e.g., social functioning). Next Steps/ Implementation: Should our results support the effectiveness of the adaptive intervention, we will disseminate peer training through the Peers in PACT and Tech into Care VA networks. We will also prepare a new ORD application to systemically investigate how the adaptive intervention can be implemented in VA.

NHLBI - National Heart Lung and Blood Institute

Project Summary Heart failure (HF) is a major source of suffering, the leading cause of death in the US (higher than dementia and cancer combined) and results in $108 billion annually in global health care costs to individuals, families and communities. Policies limiting reimbursement for HF readmissions increase strain on family caregivers to manage HF in the home with very little support. Despite advancements in guideline-directed medical therapies, HF patient outcomes are worse than the prior decade – including higher readmissions and mortality. Increased uptake of advanced HF surgical therapies including durable ventricular assist device and heart transplantation improve patient health-related quality of life (HRQOL) and survival but require high involvement of family caregivers. The impact of advanced HF care and policy falls on family caregivers who bear increased tasks and responsibilities over time while saving health systems over 7 billion per year. Caregiving for persons with HF, regardless of advanced therapies, is associated with worsening caregiver mental health, burden, stress, loss of social connections, disruptions to work, and increased financial strain. The HEart Failure Resilience Intervention for Caregivers (HEROIC) is a theory- and evidence-based primary palliative intervention including 5 individualized nurse-led sessions conducted over 10 weeks via video calls. HEROIC helps caregivers identify and address caregiving and palliative care needs for the patient, while also focusing on caregiver mental health, leveraging multi-level resilience resources: individual (goal-setting, self-care), community (social support, palliative/clinical, community) and existential (life purpose). We now propose to conduct a mechanistic randomized controlled trial to test HEROIC mechanisms of action for caregivers (N=250) and persons with advanced HF for whom they provide care, including those treated medically, or with ventricular assist device or heart transplantation (N=250) in two health systems. Aim 1 focuses on caregiver self-efficacy and burden as mechanisms of action by which HEROIC improves caregiver mental health at 12 and maintenance at 24 weeks. Aim 2 focuses on patient mechanisms - increases in HF self-care and reductions in unmet palliative care needs as mediators of improvement in patient HRQOL at 12 and 24 weeks and unplanned acute care at 1 year. Aim 3 explores differences in mechanisms and response to intervention components by HF subgroup. We will recruit a Patient and Family Advisory Council to guide the trial and intervention delivery. An exceptional study team with expertise in intersecting fields of research including HF, caregiving, and mixed methods research will guide the study. This innovative proposal directly responds to HF guidelines, policy initiatives and NHLBI strategic priorities, including NOT-HL-23-117 Palliative Care in the Care Continuum, and will provide evidence of a powerful primary palliative care strategy to demonstrate how HEROIC works (mechanisms) so that it can be scaled and adapted across settings and populations.

NIDA - National Institute on Drug Abuse

PROJECT SUMMARY Partly due to inaccurate beliefs about substance use disorder and inadequate public policies, the substance use epidemic has increased associated risks of infection with the Human Immunodeficiency Virus (HIV) and viral hepatitis (e.g., Hepatitis C Virus [HCV]) in rural regions of the United States. Identifying efficacious programs that are effective and scalable remains imperative. The proposed project, submitted in response to RFA-DA-25024, High Priority HIV and Substance Use Research, will examine the effectiveness of a virtual social intervention to increase HIV/HCV testing and prevention in rural areas of the US. The intervention convenes people with recent substance use and members of the community at large via Zoom to increase social integration, decrease negative beliefs, and improve pro-health norms in all involved. In addition to increasing social capital, the intervention provides remote access to testing and Naloxone (Narcan) and adapts to participants’ needs by promoting individual goal achievement within a group format and through an ad-hoc social platform. The research plan is supported by meticulously collected preliminary data establishing a large effect of the intervention on HIV testing, HCV testing, HIV prevention, and social integration as a composite primary outcome. The approach is also supported by impressive AI (Artificial Intelligence) data on the feasibility of developing an AI Co-Pilot to scale up this intervention by training and providing realtime assistance to community facilitators at a low cost. This five-year project will begin by preparing the infrastructure to conduct an implementation Cluster-Randomized Controlled Trial (C-RCT), including convening our Community Advisory Board (CAB) to cover at-risk rural counties and fine-tuning the AI Co-Pilot (Aim 1). We will enroll 700 participants from high-risk rural locations in the US, half using substances and the other half from the community at large, randomizing them to the AI-assisted intervention or a virtual supportgroup attention control, both with booster sessions (Aim 2). Over the next 6 months, we will measure the outcome of the intervention on a composite index of HIV and HCV testing, HIV prevention, and social integration, as well as each of those outcomes and mental health, substance use treatment seeking, substance use behaviors, and idiosyncratic goal achievement as supplementary outcomes. We will assess theoretical processes that mediate the intervention effects based on measures of norms, social support, goal session and implementation, and testing- and Narcan-kit requests. The project, which will document implementation outcomes, will be conducted by an interdisciplinary team with expertise in psychology, medicine, communication, public health, implementation science, computer science, and biostatistics, from the University of Pennsylvania and the University of North Carolina.

NIH

Background. Suicide is a top priority for the VA, claiming about 6,000 Veterans each year. VA suicide services primarily focus on immediate response to increased suicide risk but lack a focus on recovery, conceptualized by VHA as an internal process of hope, healing, empowerment, and social reconnection. The lack of a recovery focus in suicide prevention is a gap in VHA care quality. VHA Peer Specialists (PSs)—Veterans with serious mental illness (SMI) who are trained to use their experience to help other Veterans with SMI as full-fledged employees (~1,400 VA-wide)—could improve the quality of suicide prevention by making these services more recovery oriented. Based on multiple studies showing that PSs improve a range of outcomes for Veterans with SMI, the VA National Strategy for Preventing Veteran Suicide calls for the development of peer-to-peer services to help those at risk for suicide for their ability to “impart hope and motivation for achieving recovery; provide support for addressing specific stressors…and help foster a sense of meaning and purpose (p.19).” Signifi- cance: Administrative data shows that VHA PSs are already working with Veterans at risk for suicide. If PRE- VAIL-VA is effective, it could greatly increase the delivery of evidence-based services Veterans at risk for suicide receive and enhance the services by VHA Peer Specialists. Innovation: No study has tested a PS-delivered suicide prevention service in the VHA in a rigorous trial. Specific Aims. The proposed study is a Hybrid Type 1 randomized trial with two aims: Aim 1: Deliver PREVAIL-VA and compare recipients of PREVAIL-VA and Usual Care on suicide-related and recovery outcomes. Aim 2: Collect qualitative data on PREVAIL-VA helpfulness, and implementation barriers and facilitators using the Consolidated Framework for Implementation Research (CFIR) and rapid qualitative analysis. Methodology. This application proposes to test in two VA health sys- tems—Pittsburgh and Maryland—a promising PS-based approach to helping VA patients with a high risk of suicide, called PREVAIL-VA. Adapted from a civilian version with VA PS and suicide stakeholder input, PRE- VAIL-VA (Peers for Valued Living) provides 12, one-on-one sessions over about three months between a PS and a Veteran that involve semi-structured conversations focused on hope, belongingness, and safety. Session context is flexible, driven by the needs of the individual and by the ILSM (Invite, Learn, Share, Motivate) structure that guides how PSs interact with those whom they work. A civilian pilot study was promising; preliminary findings of a larger civilian trial showed small improvements. Veterans with documented suicide risk at each site (n=153) will be randomized to PREVAIL-VA or Usual Care (total N=306). Each site will have two trained PSs, who will each deliver PREVAIL-VA to ~40 Veterans over ~3 years (~4 Veterans at any one time). PSs will be trained and receive an hour of group supervision weekly by the PREVAIL-VA developer and licensed psychologists, who will also be available for emergencies. Sessions will be taped and 15% rated for fidelity on standardized measures. Each Veteran will be assessed at baseline, post-intervention, and six months post-intervention on the primary outcome of suicide risk with additional primary outcomes focusing on recovery domains such as self-rated com- munity integration; sense of hope, meaning, and purpose. Secondary outcomes will include suicide attempts, depression, belonging, and acute care visits for suicide-related reasons. The primary analytic strategy will be a generalized mixed-effect model approach including intervention group, time, and time by group interaction terms. Relevant covariates will include site, fidelity ratings, treatment attendance, VA service use, and demographic variables. At each site, all PSs and a subset of PREVAIL-VA Veterans, VHA clinicians whose patients received PREVAIL-VA, and clinical leaders will participate in qualitative data collection (periodic reflection, interview, focus group) about helpfulness of PREVAIL-VA and relevant CFIR-based implementation factors that could inform its future adoption. Qualitative data will be analyzed with a `rapid analysis' approach. Next Steps/Implementation. If effective, we will develop an implementation toolkit and work with partners to teach PREVAIL-VA to all PSs.

Texas Health and Human Services Commission

Grants to nonprofits and community organizations providing direct services to vulnerable Texans including mental health support, substance abuse treatment, and family services.

Texas Veterans Commission

Provides competitive grants to eligible organizations to develop, provide, or enhance services for Texas veterans and their families, including mental health, housing, employment, and legal services.